Original Article

Korean J Hematol 2007; 42(4):

Published online December 30, 2007

https://doi.org/10.5045/kjh.2007.42.4.325

© The Korean Society of Hematology

고용량 스테로이드에도 반응이 없는 스테로이드저항성 급성 이식편대숙주질환에 대한 체외광분반술의 효과

김성용, 이종욱, 민창기, 조병식, 엄기성, 김유진, 이석, 김희제, 조석구, 김동욱, 민우성, 김춘추

가톨릭대학교 의과대학 내과학교실, 가톨릭조혈모세포이식센터

Effect of Extracorporeal Photopheresis on Steroid Resistant Acute GVHD Refractory to High Dose Steroid Treatment

Sung Yong Kim, Jong Wook Lee, Chang Ki Min, Byung Sik Cho, Ki Seong Eom, Yoo Jin Kim, Seok Lee, Hee Je Kim, Seok Goo Cho, Dong Wook Kim, Woo Sung Min, Chun Choo Kim

Department of Internal Medicine, Catholic Hematopoietic Stem Cell Transplantation Center,
The Catholic University of Korea, Seoul, Korea

Abstract

Background:
The mortality of patients with steroid resistant acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) is high due to multiple organ failure and infection. Recently, the use of extracorporeal photopheresis (ECP), which is believed to have a low risk of infection, has been applied for the treatment of GVHD.
Methods:
Of 23 patients who were steroid resistant acute GVHD that was resistant even to high dose steroid treatment as second-line treatment, 10 patients received ECP (ECP group) and 13 patients received a third-line treatment other than ECP (non-ECP group). The outcome including the response rate and survival for the ECP group and non-ECP group was analyzed.
Results:
The response rate of the ECP group including complete remission and partial remission, was 30%. The survival rate was 30% for the ECP group and 0% for the non-ECP group. The estimated mean survival time was 229.3±89.3 days for the ECP group and 41.8±14.6 days for the non-ECP group (P=0.028).
Conclusion:
ECP can be considered as a treatment option for the steroid resistant acute GVHD that is refractory to high dose steroid treatment.

Keywords Steroid, Graft-versus-host disease, Hematopoietic stem cell transplantation, Extracorporeal photopheresis

Article

Original Article

Korean J Hematol 2007; 42(4): 325-334

Published online December 30, 2007 https://doi.org/10.5045/kjh.2007.42.4.325

Copyright © The Korean Society of Hematology.

고용량 스테로이드에도 반응이 없는 스테로이드저항성 급성 이식편대숙주질환에 대한 체외광분반술의 효과

김성용, 이종욱, 민창기, 조병식, 엄기성, 김유진, 이석, 김희제, 조석구, 김동욱, 민우성, 김춘추

가톨릭대학교 의과대학 내과학교실, 가톨릭조혈모세포이식센터

Effect of Extracorporeal Photopheresis on Steroid Resistant Acute GVHD Refractory to High Dose Steroid Treatment

Sung Yong Kim, Jong Wook Lee, Chang Ki Min, Byung Sik Cho, Ki Seong Eom, Yoo Jin Kim, Seok Lee, Hee Je Kim, Seok Goo Cho, Dong Wook Kim, Woo Sung Min, Chun Choo Kim

Department of Internal Medicine, Catholic Hematopoietic Stem Cell Transplantation Center,
The Catholic University of Korea, Seoul, Korea

Abstract

Background:
The mortality of patients with steroid resistant acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) is high due to multiple organ failure and infection. Recently, the use of extracorporeal photopheresis (ECP), which is believed to have a low risk of infection, has been applied for the treatment of GVHD.
Methods:
Of 23 patients who were steroid resistant acute GVHD that was resistant even to high dose steroid treatment as second-line treatment, 10 patients received ECP (ECP group) and 13 patients received a third-line treatment other than ECP (non-ECP group). The outcome including the response rate and survival for the ECP group and non-ECP group was analyzed.
Results:
The response rate of the ECP group including complete remission and partial remission, was 30%. The survival rate was 30% for the ECP group and 0% for the non-ECP group. The estimated mean survival time was 229.3±89.3 days for the ECP group and 41.8±14.6 days for the non-ECP group (P=0.028).
Conclusion:
ECP can be considered as a treatment option for the steroid resistant acute GVHD that is refractory to high dose steroid treatment.

Keywords: Steroid, Graft-versus-host disease, Hematopoietic stem cell transplantation, Extracorporeal photopheresis

Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download